Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer

被引:52
|
作者
Cron, Kyle R. [1 ]
Zhu, Kaya [1 ]
Kushwaha, Deepa S. [1 ]
Hsieh, Grace [1 ]
Merzon, Dmitry [1 ]
Rameseder, Jonathan [2 ]
Chen, Clark C. [3 ]
D'Andrea, Alan D. [1 ,4 ]
Kozono, David [1 ]
机构
[1] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[2] MIT, Cambridge, MA 02139 USA
[3] Univ Calif San Diego, Div Neurosurg, San Diego, CA 92103 USA
[4] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA
来源
PLOS ONE | 2013年 / 8卷 / 09期
基金
美国国家卫生研究院;
关键词
NF-KAPPA-B; DOUBLE-STRAND BREAKS; MULTIPLE-MYELOMA; MAMMALIAN-CELLS; GENE-EXPRESSION; SOLID TUMORS; BORTEZOMIB; ADENOCARCINOMA; RECOMBINATION; CHEMOTHERAPY;
D O I
10.1371/journal.pone.0073710
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Despite optimal radiation therapy (RT), chemotherapy and/or surgery, a majority of patients with locally advanced non-small cell lung cancer (NSCLC) fail treatment. To identify novel gene targets for improved tumor control, we performed whole genome RNAi screens to identify knockdowns that most reproducibly increase NSCLC cytotoxicity. These screens identified several proteasome subunits among top hits, including the topmost hit PSMA1, a component of the core 20 S proteasome. Radiation and proteasome inhibition showed synergistic effects. Proteasome inhibition resulted in an 80-90% decrease in homologous recombination (HR), a 50% decrease in expression of NF-kappa B-inducible HR genes BRCA1 and FANCD2, and a reduction of BRCA1, FANCD2 and RAD51 ionizing radiation-induced foci. I kappa B alpha RNAi knockdown rescued NSCLC radioresistance. Irradiation of mice with NCI-H460 xenografts after inducible PSMA1 shRNA knockdown markedly increased murine survival compared to either treatment alone. Proteasome inhibition is a promising strategy for NSCLC radiosensitization via inhibition of NF-kappa B-mediated expression of Fanconi Anemia/HR DNA repair genes.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
    Assi, Hazem I.
    Kamphorst, Alice O.
    Moukalled, Nour M.
    Ramalingam, Suresh S.
    CANCER, 2018, 124 (02) : 248 - 261
  • [32] Tyrosine kinase inhibitors in the management of non-small cell lung cancer
    Perol, M.
    Arpin, D.
    REVUE DES MALADIES RESPIRATOIRES, 2007, 24 (08) : S188 - S197
  • [33] Emerging evidence of immunocheckpoint inhibitors in non-small cell lung cancer
    Borghaei, Hossein
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
    Straughan, David M.
    Azoury, Said C.
    Shukla, Vivek
    CURRENT DRUG TARGETS, 2016, 17 (06) : 739 - 745
  • [35] Dietary Aromatase Inhibitors in Human Non-Small Cell Lung Cancer
    Sen, Alaattin
    Akca, Hakan
    Celik, Gurbet
    DRUG METABOLISM REVIEWS, 2010, 42 : 171 - 171
  • [36] Emerging protein kinase inhibitors for non-small cell lung cancer
    Liu, Stephen V.
    Subramaniam, Deepa
    Cyriac, George C.
    Abdul-Khalek, Feras J.
    Giaccone, Giuseppe
    EXPERT OPINION ON EMERGING DRUGS, 2014, 19 (01) : 51 - 65
  • [37] Discovery of CLKs inhibitors for the treatment of non-small cell lung cancer
    Hu, Tianxing
    Huang, Jiali
    Chen, Rui
    Zhang, Hui
    Liu, Mai
    Wang, Renbing
    Zhou, Wenyi
    Huang, Dechun
    Cao, Mingkang
    Li, Depeng
    Li, Zhiyu
    Wu, Hongxi
    Bian, Jinlei
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 280
  • [38] Highlights on immune checkpoint inhibitors in non-small cell lung cancer
    Shen, Meng
    Ren, Xiubao
    TUMOR BIOLOGY, 2017, 39 (03)
  • [39] Novel KRAS Inhibitors for Treating Non-small Cell Lung Cancer
    Sabnis, Ram W.
    ACS MEDICINAL CHEMISTRY LETTERS, 2024, 15 (08): : 1201 - 1202
  • [40] The potential role of mTOR inhibitors in non-small cell lung cancer
    Gridelli, Cesare
    Maione, Paolo
    Rossi, Antonio
    ONCOLOGIST, 2008, 13 (02): : 139 - 147